Quick Takeaways: Why It Matters? Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary onc...
Featured Article Cover Story Research Updates Regulatory Approval Product Launches Elanco Launches $25 Million Venture Fund Innovation platform Elanco Animal Health plans to launch Elanco Ventures, a $25 million corporate venture platform to back early-stage animal health innovation. Key h...
The US FDA’s 2025 animal health approvals highlight a transformative year for veterinary medicine, with major advances spanning companion animal therapeutics, livestock productivity, poultry health, parasitic disease management, diagnostics, oncology, and genetic innovation. The latest wav...
Quick Takeaways: Why It Matters? Elanco is tightening its premium position in canine vaccines by launching the first 0.5 mL combo shot that covers both Lyme disease and leptospirosis in a single, low-volume dose, using its PureFil technology to support fewer reactions and more co...
Quick Takeaways: Why It Matters? Gelteq’s canine palatability trials with Kemin confirm that its gel-based delivery platform can effectively mask bitter compounds and deliver strong acceptance across multiple flavor profiles, even with naturally unpalatable ingredients. This is a key enabl...
Featured Article Cover Story Research & Innovation Financing & Partnerships Product Launches Mergers & Acquisitions Regulatory Updates At a Glance Merck Animal Health Expands Poultry Tech Portfolio Acquisition Merck Animal Health has agreed to acquire TARGAN, adding advanced po...
Quick Takeaways: Why It Matters? The FDA’s EUA for generic Nitenpyram Tablets creates an immediate, affordable, OTC treatment option for pet owners facing necrotizing worm (NWS) fly infestations in dogs, puppies, cats, and kittens ≥2 lb and ≥4 weeks old. This broadens access to a cost...
Quick Takeaways: Why It Matters? Unlike drugs that carry safety concerns or diminishing effectiveness, LIFU aims to provide a non-invasive alternative to nerve blocks and radiofrequency ablation without systemic exposure, which could reduce reliance on medications and invasive procedures. ...
Quick Takeaways: Why It Matters? Ceva is using this deal to cement a differentiated position in swine health by owning Europe’s only commercial vaccine against swine dysentery, a disease that drives major losses in pig production. This will also deepen Ceva’s R&D pipeline and...
Quick Takeaways: Why It Matters? Cronus Pharma is bringing price competition to a key canine heart failure drug class by launching the first FDA‑approved bioequivalent chewable to Vetmedin, available nationwide through vet distributors. For the market, this should lo...
